GenesisCare inks two strategic agreements in cancer medicine

Pharma News: Theranostics have unprecedented value to diagnose and treat cancers, and a number of novel theranostics are under development and expected to enter clinical trials and care in the near future. In the lead up to World Theranostics Day this Friday, 31^st March, GenesisCare has announced two strategic agreements to identify and proactively pursue clinical research opportunities in the fields of molecular imaging and theranostics.

GenesisCare’s Chief Scientific Officer, Theranostics, Research & Insights, Dr Danielle Meyrick, said “Over the last decade we have made significant progress in the advancement of theranostics in Australia, both in terms of the development of new therapies and advanced imaging technologies, as well as the emergence of a network of nuclear medicine physicians and physicists with the expertise and deep knowledge base to deliver the best possible care for patients.”

“GenesisCare hopes to unlock the full potential of theranostics both here in Australia and abroad, to ensure the patient benefits of these recent therapeutic and technological advancements are fully realised,” Dr Meyrick.

Professor Rodney Hicks, PreMIT Founder, Chairman, and Chief Medical Officer, said “PreMIT is delighted to be partnering with GenesisCare, who share our vision of democratising and scaling patient access to theranostics and precision medicine worldwide.”

“Together, PreMIT and GenesisCare are seeking to develop a differentiated clinical trial capability to increase patient access to novel therapies, drive greater collaboration within the academic and biotechnology ecosystem, and facilitate efficient and integrated research data exchange.”

“We see a future where theranostics will become a key pillar of modern cancer medicine, however a concerted effort is required globally by medical experts, industry, academia and governments. Collectively, we need to build on the great progress we have already made, to collaborate, knowledge-share, and increase patient access to new therapies in a faster and more affordable way,” said Professor Hicks.

In a busy week for GenesisCare, the organisation has also inked a multi-year strategic research partnership with Radiopharm Theranostics in an effort to develop novel radiopharmaceuticals and address unmet needs in oncology.

“Radiopharmaceuticals are quickly becoming a highly promising therapeutic frontier in oncology, offering new hope to patients who may have exhausted all other treatment options,” Radiopharm Theranostics CEO and managing director Riccardo Canevari said.

“We are delighted to be extending and strengthening our partnership with GenesisCare, a world leader in cancer care, to advance the future of radiopharmaceuticals and improve access to innovative therapies for patients all over the world.”

Dr Danielle Meyrick commented “We are delighted to be partnering with Radiopharm on its exciting pipeline of research in Australia. This R&D collaboration brings together two Australian-founded healthcare companies who share an interest in investigating and developing new therapies.”

In reimagining healthcare, Health Industry Hub^TM is the ONLY one-stop-hub uniting the diversity of Pharma, MedTech, Diagnostics & Biotech sectors to inspire meaningful change. The exclusive leadership and influencer podcasts and vodcasts offer unparalleled insights and add immense value to our breaking news coverage.

The Health Industry Hub^TM content is copyright protected. Access is available under individual user licenses. Please click here to subscribe and visit T&Cs here.